Merck & Co., Inc. is 76.7x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $3.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CPRX | MRK |
|---|---|---|
| Market cap | $3.84 B | $294.13 B |
| US-listed rank | #1606 | #44 |
| Revenue (latest FY) | $588.99M | $65.01B |
| Net income (latest FY) | $214.33M | $18.25B |
| Net margin | 36.4% | 28.1% |
| P/E (trailing FY) | 17.9 | 16.1 |
| SEC filings | 1,337 | 996 |
Merck & Co., Inc. is 76.7x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $3.84 B).
In their latest fiscal years, CATALYST PHARMACEUTICALS, INC. reported $588.99M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: CATALYST PHARMACEUTICALS, INC. and Merck & Co., Inc., or browse the full rankings.